DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
前收盘价
US$179.25
+US$2.23 · +1.26%
盘中时间采用ET。市场数据可能有所延迟。
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
日内区间
当前US$179.25
52周区间
当前US$179.25
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
54
合理估值
情绪
60
多空交织
风险
20
低风险
动量
72
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
日内区间
当前US$179.25
52周区间
当前US$179.25
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 136.43亿 USD | 128.16亿 USD | 121.4亿 USD | 116.1亿 USD | 116.19亿 USD |
| 销货成本 | 99.59亿 USD | 85.99亿 USD | 83.2亿 USD | 82.1亿 USD | 79.72亿 USD |
| 毛利 | 36.84亿 USD | 42.17亿 USD | 38.2亿 USD | 34亿 USD | 36.46亿 USD |
| 销售、一般及管理费用 | 16.74亿 USD | 15.38亿 USD | 14.74亿 USD | 13.55亿 USD | 11.95亿 USD |
| 营业费用 | 16.74亿 USD | 21.27亿 USD | 22.18亿 USD | 20.61亿 USD | 18.49亿 USD |
| 利息支出 | 5.5亿 USD | 4.7亿 USD | 3.99亿 USD | 3.57亿 USD | 2.85亿 USD |
| 折旧和摊销 | 7.15亿 USD | 7.24亿 USD | 7.45亿 USD | 7.33亿 USD | 6.81亿 USD |
| 营业利润 | 20.11亿 USD | 20.9亿 USD | 16.03亿 USD | 13.39亿 USD | 17.97亿 USD |
| 净利润 | 7.47亿 USD | 9.36亿 USD | 6.92亿 USD | 5.6亿 USD | 9.78亿 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2013年9月9日 | 2:1 | — | — |
股票拆分 | 2004年6月16日 | 3:2 | — | — |
股票拆分 | 1997年10月21日 | 5:3 | — | — |
已生效 2013年9月9日
2:1
已生效 2004年6月16日
3:2
已生效 1997年10月21日
5:3
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T115.73亿0.01%129.35万亿 JPY0.09%JP¥122,850—
Invesco S&P 500 Equal Weight ETFRSP1.92亿0.20%977.83亿 USD0.20%US$213.04—
Vanguard Morningstar Total Stock Market ETFVTI1.8亿0.01%2.3万亿 USD0.03%US$381.94—
Vanguard S&P 500 ETFVOO1.5亿0.01%1.8万亿 USD0.03%US$715.59—
Vanguard Morningstar Small-Cap ETFVB1.3亿0.07%1853亿 USD0.03%US$289.48—
Vanguard Morningstar Small-Cap Value ETFVBR8255.82万0.12%682亿 USD0.05%US$234.43—
iShares Core S&P 500 ETFIVV7962.86万0.01%8964.4亿 USD0.03%US$781.97—
State Street SPDR S&P 500 ETFSPY7311.49万0.01%8172亿 USD0.09%US$778.57—
State Street SPDR S&P 500 ETF1557.T
Invesco S&P 500 Equal Weight ETFRSP
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard S&P 500 ETFVOO
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Value ETFVBR
iShares Core S&P 500 ETFIVV
State Street SPDR S&P 500 ETFSPYAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。